stockrow
Friday 6 November 2026
Export ANIK’s income statement to Excel — free account
Anika Therapeutics Inc.
ANIK Healthcare Drug Manufacturers Specialty & Generic
Anika Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $112.8 million, down 5.91% from fiscal 2024.
- Revenue
- +15.6%
- EPS
- +189.3%
- Free cash flow
- +61.6%
Quarter to June 2026, against a year earlier
19.31
1.09
−5.34%
Follow ANIK
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 123.55 | 0.00 | 26.87 | 25.85 | 25.19 | 22.57 |
Piotroski F-Score |
6 | 5 | 4 | 5 | 8 | 3 | 8 | 6 | 5 | 6 |
Altman Z-Score |
3.13 | 4.52 | 5.12 | 5.76 | 6.96 | 5.55 | 12.90 | 21.49 | 27.39 | 27.60 |
P/S ratio |
1.22 | 2.02 | 2.75 | 3.77 | 3.49 | 4.93 | 6.39 | 4.60 | 7.06 | 7.12 |
P/FCF ratio |
27.77 | 0.00 | 0.00 | 0.00 | 158.57 | 56.28 | 21.42 | 16.04 | 25.14 | 70.51 |
Altman Z″-Score (non-manufacturers) |
6.68 | 7.22 | 8.59 | 9.42 | 9.77 | 7.04 | 14.59 | 25.58 | 22.34 | 21.50 |
Beneish M-Score |
(2.84) | (2.62) | (3.11) | (2.24) | (2.23) | (2.51) | (2.32) | (2.90) | (2.85) | (1.95) |
P/Operating CF |
29.72 | 153.17 | 91.29 | 892.43 | 115.38 | 248.82 | 56.23 | 48.48 | 114.64 | 121.21 |
P/B ratio |
0.96 | 1.57 | 1.56 | 1.50 | 1.80 | 2.36 | 2.54 | 1.84 | 3.04 | 3.30 |
Price to Tangible BV |
1.03 | 1.68 | 1.64 | 2.11 | 2.62 | 3.72 | 2.68 | 1.97 | 3.27 | 3.58 |
EV/Sales |
0.93 | 1.77 | 2.39 | 3.23 | 3.02 | 4.37 | 4.96 | 3.09 | 5.67 | 5.91 |
EV/EBITDA |
0.00 | 38.61 | 3.73 | 20.26 | 18.61 | 14.72 | 14.13 | 11.96 | 12.86 | 11.24 |
EV/Operating CF |
9.41 | 39.18 | (161.28) | 83.45 | 53.19 | 43.66 | 15.37 | 9.35 | 15.76 | 24.99 |
EV/FCF |
21.22 | (90.81) | (39.97) | (119.57) | 137.25 | 49.87 | 16.64 | 10.79 | 20.20 | 58.56 |
Quick Ratio |
3.71 | 3.40 | 3.06 | 4.33 | 4.17 | 3.32 | 12.78 | 15.93 | 13.85 | 17.32 |
Current Ratio |
4.72 | 4.88 | 5.26 | 6.07 | 5.66 | 4.81 | 14.39 | 17.98 | 15.78 | 19.37 |
Net Debt/EBITDA |
10.80 | (10.15) | (0.89) | (4.75) | (3.93) | (2.54) | (4.60) | (5.83) | (3.14) | (2.30) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.57 | 0.51 | 0.39 | 0.33 | 0.41 | 0.37 | 0.38 | 0.38 | 0.43 | 0.43 |
Operating CF/Net income |
(1.03) | (0.10) | 0.02 | (0.30) | 2.03 | (0.54) | 1.36 | 1.87 | 1.28 | 0.75 |
Capex/Depreciation |
(1.09) | (0.73) | (0.07) | (0.52) | (0.24) | (0.02) | (0.47) | (0.84) | (2.09) | (3.75) |
| (7.32%) | (30.79%) | (33.21%) | (5.19%) | 1.48% | (8.55%) | 9.85% | 7.10% | 13.09% | 15.01% | |
| (5.54%) | (23.82%) | (26.68%) | (4.27%) | 1.16% | (6.89%) | 8.92% | 6.67% | 12.17% | 13.68% | |
ROIC |
(8.03%) | (3.24%) | 0.37% | 1.15% | 0.85% | (10.17%) | 20.69% | 13.00% | 26.90% | 32.27% |
Return on Tangible Assets |
(8.93%) | (43.59%) | (48.72%) | (7.82%) | 2.22% | (12.55%) | 10.12% | 7.62% | 12.76% | 15.21% |
Average Days of Receivables |
76.64 | 71.82 | 79.65 | 111.04 | 73.70 | 67.43 | 73.50 | 71.84 | 76.67 | 97.44 |
Research and Development Expense of Revenue |
22.84% | 21.30% | 18.02% | 16.10% | 18.49% | 17.96% | 14.54% | 17.23% | 16.56% | 10.38% |
Selling, General and Administrative Expense of Revenue |
43.51% | 46.33% | 49.61% | 45.01% | 50.13% | 46.04% | 30.49% | 32.53% | 18.99% | 17.42% |
Intangible Assets out of Total Assets |
0.05 | 0.05 | 0.04 | 0.23 | 0.26 | 0.27 | 0.05 | 0.06 | 0.07 | 0.07 |
Share Based Compensation of Revenue |
8.94% | 10.95% | 12.62% | 12.58% | 7.50% | 4.13% | 5.31% | 10.46% | 5.12% | 3.28% |
Graham Net Nets |
0.41 | 0.27 | 0.32 | 0.25 | 0.21 | 0.13 | 0.26 | 0.39 | 0.23 | 0.21 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 11.41 | 0.00 | 29.78 | 23.11 | 29.78 | 27.53 |
Earnings Yield |
(7.91%) | (23.39%) | (24.93%) | (3.49%) | 0.81% | (3.72%) | 3.72% | 3.87% | 3.97% | 4.43% |
Free Cash Flow Yield |
3.60% | (0.96%) | (2.17%) | (0.72%) | 0.63% | 1.78% | 4.67% | 6.23% | 3.98% | 1.42% |
Revenue per Share |
7.87 | 8.15 | 8.24 | 7.82 | 10.26 | 9.17 | 8.12 | 7.31 | 7.78 | 7.04 |
Operating CF per Share |
0.78 | 0.37 | (0.12) | 0.30 | 0.58 | 0.92 | 2.62 | 2.42 | 2.80 | 1.67 |
Capex per Share |
(0.43) | (0.53) | (0.37) | (0.51) | (0.36) | (0.11) | (0.20) | (0.32) | (0.62) | (0.95) |
Free Cash Flow per Share |
0.35 | (0.16) | (0.49) | (0.21) | 0.23 | 0.80 | 2.42 | 2.10 | 2.18 | 0.71 |
Cash per Share |
4.01 | 3.78 | 4.69 | 5.93 | 6.55 | 6.91 | 13.10 | 11.01 | 10.79 | 8.50 |
Shareholders Equity per Share |
10.01 | 10.46 | 14.48 | 19.61 | 19.94 | 19.15 | 20.42 | 18.25 | 18.08 | 15.17 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
10.01 | 10.46 | 14.48 | 19.61 | 19.94 | 19.15 | 20.42 | 18.25 | 18.08 | 15.17 |
Free Cash Flow |
4.96 | (2.33) | (7.21) | (3.08) | 3.25 | 11.44 | 34.18 | 30.26 | 31.83 | 10.43 |
Working Capital |
81.45 | 90.35 | 132.25 | 141.63 | 138.73 | 140.52 | 218.03 | 191.65 | 193.25 | 161.64 |
Capital Expenditures |
(6.23) | (7.73) | (5.43) | (7.49) | (5.14) | (1.63) | (2.83) | (4.66) | (8.98) | (14.01) |
Net Current Asset Value |
56.55 | 64.90 | 104.94 | 105.98 | 108.08 | 84.18 | 191.97 | 187.56 | 187.20 | 152.97 |
EV/EBIT |
0.00 | 0.00 | 341.66 | 100.25 | 170.78 | 0.00 | 16.60 | 15.01 | 14.06 | 12.07 |
Capex to Sales |
0.06 | 0.06 | 0.04 | 0.07 | 0.03 | 0.01 | 0.02 | 0.04 | 0.08 | 0.14 |
Price to Operating Income |
0.00 | 0.00 | 393.49 | 116.96 | 197.32 | 0.00 | 21.38 | 22.32 | 17.50 | 14.54 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.14 | 0.27 | 2.04 | 0.30 | 0.45 | 1.33 | 0.12 | 0.10 | 0.08 | 0.07 |
Cash ROIC |
2.47% | (1.11%) | (2.57%) | (0.83%) | 0.85% | 3.09% | 7.22% | 7.16% | 7.57% | 3.00% |
Accounts Receivable Turnover |
4.77 | 4.80 | 3.96 | 3.53 | 5.48 | 5.53 | 5.23 | 4.73 | 4.41 | 4.20 |
Accounts Payable Turnover |
8.41 | 7.44 | 5.01 | 4.86 | 7.81 | 9.59 | 8.24 | 6.33 | 6.05 | 4.53 |
Inventory Turnover |
2.30 | 1.82 | 1.19 | 1.07 | 1.58 | 1.80 | 1.33 | 1.44 | 1.44 | 1.55 |
Average Days of Payables |
44.99 | 46.69 | 59.09 | 81.56 | 42.96 | 53.38 | 48.65 | 36.68 | 90.00 | 34.99 |
Days of Inventory on Hand |
139.91 | 197.92 | 233.04 | 357.43 | 202.67 | 274.56 | 279.27 | 248.55 | 293.92 | 242.80 |
Average Receivables |
23.64 | 24.98 | 30.49 | 32.24 | 26.97 | 23.59 | 21.93 | 22.30 | 25.71 | 24.63 |
Average Payables |
5.83 | 5.91 | 7.63 | 8.35 | 8.31 | 6.41 | 3.49 | 4.95 | 4.53 | 5.30 |
Average Inventory |
21.30 | 24.12 | 32.10 | 37.89 | 41.11 | 34.10 | 21.65 | 21.67 | 19.01 | 15.46 |
Average Assets |
196.51 | 236.69 | 309.88 | 348.33 | 356.57 | 348.16 | 304.85 | 280.81 | 261.43 | 238.00 |
Average Common Equity |
148.73 | 183.13 | 248.91 | 286.32 | 279.74 | 280.39 | 276.00 | 263.55 | 243.13 | 216.81 |
Columns are period end dates